CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen 5th Annual Oncology Innovation Summit, taking place virtually on Tuesday, May 28, 2024 at 9:30 a.m. ETGoldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jurisdi ...

Exhibit 99.1 Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 Cambridge, Mass. – May 2, 2024 – Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-3923475 (State or other jurisdicti ...

Exhibit 99.1 Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jurisdic ...

财务状况 - 截至2023年第一季度末，公司现金、现金等价物和投资总额约为9.38亿美元[6] - 公司预计当前的现金流足以支持运营计划至2025年[9] 临床试验与产品研发 - RLY-4008针对FGFR2突变和野生型的乳腺癌患者，预计美国年患者数量为11,000至35,000人[8] - RLY-2608针对PI3Kα的临床数据预计在2023年上半年发布[9] - RLY-5836的临床试验预计在2023年第二季度启动[9] - RLY-2139（CDK2抑制剂）预计在2023年进行临床试验[9] - RLY-4008的关键数据更新预计将在2024年进行[9] - RLY-5836的临床试验于2023年4月开始，涉及约15名PIK3CA突变的晚期实体瘤患者[69] - RLY-2139的临床试验正在进行中，预计将在2023年下半年提供更多数据更新[81] - RLY-2608的临床数据将在2023年上半年公布[81] 市场机会与需求 - FGFR2相关癌症的年患者数量约为11,000至35,000人，显示出高未满足的医疗需求[14] - 美国每年约有196,000例HR+/HER2-乳腺癌新病例，其中约50,000例患者需接受后续治疗[30] - 预计2023年将有约76,000至238,000名患者适合PI3Kα治疗[80] - SHP2组合治疗的患者数量预计为37,000至69,000名[80] 产品效果与安全性 - RLY-4008在70 mg QD剂量下，FGFRi-Naïve Fusion+ CCA患者的最佳总体反应率（ORR）为88%[21] - 在所有剂量下，FGFRi-Naïve Fusion+ CCA患者的ORR为63%[23] - RLY-4008在FGFR2靶向抑制方面表现出90%以上的靶向抑制率[27] - RLY-2608在400mg BID单药和≥600mg BID联合用药时，持续抑制pAKT达到80%以上[46] - RLY-2608的安全性良好，未观察到3级高血糖[46] - RLY-5836在治疗过程中显示出良好的耐受性和初步抗肿瘤活性[75] 未来展望 - 预计2023年下半年将披露肿瘤无关扩展队列的数据[26] - 预计2023年将提名ERα降解剂的开发候选药物，针对每年约195,000名HR+/HER2-乳腺癌患者[73] - RLY-2608的扩展队列将在2023年下半年启动，预计2024年将发布更多PIK3CA系列的临床数据[75] 合作与财务支持 - Relay Therapeutics已收到1.05亿美元的预付款和里程碑付款，外加高达6.9亿美元的潜在额外里程碑[77] - 公司正在进行5个未披露的临床试验项目[81]

be30ou06-30-202s UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-3923475 (State or other jurisdicti ...